Developer docs
API playgroundTry for free, no card

Search company profiles

Amber Therapeutics

Full company profile

uuid0000mff

Namestring
Amber Therapeutics
Legal namestring
Amber Therapeutics Ltd.
Websiteurl
amber-tx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Amber Therapeutics is a UK-based, venture-backed medical device company founded in 2021 by Aidan Crawley, Tim Denison, Stefan De Wachter, and Charles Knowles to develop adaptive neuromodulation therapies for areas of unmet clinical need. The company's lead program, Amber-UI, is a fully implantable neurostimulation therapy that targets the pudendal nerve to treat women with mixed urinary incontinence (MUI) — a population of roughly 40 million symptomatic women in the US of whom only 16 million receive any therapy. Amber's core technology is the Picostim System running the DyNeuMo firmware platform, which combines integrated sensing with adaptive closed-loop stimulation in a single implantable pulse generator, originally developed for deep brain stimulation and acquired via the September 2023 Bioinduction transaction.

The Picostim DyNeuMo platform is positioned as the first singular therapy capable of addressing both urge and stress components of MUI in a single device, validated in the AURA-2 first-in-human study (13 women at University Hospital Antwerp) which met primary safety/feasibility endpoints and showed pilot efficacy and quality-of-life improvements. A US registration trial is planned for 2026 to support FDA approval, and Amber has extended its pipeline through ongoing studies (SPARKS, CADET, MINDS, EPIONE) and a December 2025 collaboration with MintNeuro on next-generation miniaturized semiconductor chips.

Amber is pre-revenue and pre-commercial; its go-to-market is built around clinical trials with academic medical centers and a planned enterprise field sales motion to urology/pelvic-health specialists and hospital systems once regulatory approval is obtained. Revenue mechanics, once commercial, will be hardware sales of the implantable Picostim device plus procedure-driven service revenue, with pricing not publicly disclosed and distribution expected through direct engagement with hospital procurement. The company has raised $100 million in Series A financing (June 2024, led by NEA) and is backed by F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises, and 8VC.

Short descriptiontext

Amber Therapeutics is a UK medical device company developing Amber-UI, a fully implantable, closed-loop neuromodulation therapy that targets the pudendal nerve to treat women with mixed urinary incontinence, with a US registration trial planned for 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable neuromodulation devices, bioelectronic medical devices, urinary incontinence therapy, adaptive neurostimulation, pelvic floor neuromodulation
Industry1 code
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Implantable Neuromodulation Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Implantable Neuromodulation Devices
TypeHardware Sales
Description

Amber Therapeutics generates revenue through the sale of its Picostim System and Amber-UI therapy devices - fully implantable neurostimulation devices for treating mixed urinary incontinence. The company also acquired Bioinduction Limited, consolidating itself as an integrated manufacturer and developer of neuromodulation devices.

amber-tx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Amber-UI
Description

Adaptive neuromodulation therapy for treating women suffering with mixed urinary incontinence (both urge and stress incontinence), targeting the pudendal nerve with a fully implantable device.

amber-tx.com
+2 more records
Core offering1 text field

Amber Therapeutics develops and manufactures fully implantable neuromodulation devices, primarily the Picostim System powered by its DyNeuMo firmware, to deliver adaptive pudendal nerve stimulation. Its lead therapy, Amber-UI, is the first single therapy designed to treat mixed urinary incontinence (both urge and stress incontinence) in women. The company is advancing the therapy through clinical trials (AURA-2) toward FDA approval, and serves as an integrated developer and manufacturer following its 2023 acquisition of Bioinduction Limited.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Primary aim of demonstrating safety and feasibility of surgical procedure fulfilled in AURA-2 study
+3 more records
Product overview1 text field

Amber Therapeutics develops a unified product ecosystem centered on its Picostim System with DyNeuMo firmware platform, which serves as the foundation for its Amber-UI therapy. The Picostim is a fully implantable device that combines stimulation and sensing capabilities to deliver adaptive closed-loop neuromodulation for mixed urinary incontinence. The company also maintains the legacy Finetech-Brindley SARS System (no longer for new patients). The portfolio architecture consists of the Picostim hardware platform with integrated sensors, the DyNeuMo adaptive firmware enabling real-time therapy adjustment, and the Amber-UI therapy which represents the configured treatment for urinary incontinence.

Product and service3 records
1Amber-UI
CategoryImplantable Neuromodulation Therapy
Description

Amber-UI is an adaptive neuromodulation therapy for treating women with mixed urinary incontinence (both urge and stress incontinence). It uses a fully implantable Picostim System that targets the pudendal nerve, combining stimulation and sensing of physiological responses through adaptive algorithms configurable to individual patient needs. It is intended for healthcare providers and urology/pelvic health specialists treating refractory patients.

2Picostim System
CategoryImplantable Neurostimulator Hardware
Description

Picostim is a fully implantable neurostimulation device with integrated sensors capable of both stimulating and sensing physiological responses. It is configured to deliver adaptive closed-loop neuromodulation targeting the pudendal nerve for the Amber-UI therapy and is sold to clinical and hospital customers.

3Finetech-Brindley SARS System
CategoryLegacy Implantable Bladder Control Device
Description

The Finetech-Brindley SARS System is a legacy implantable bladder control system for patients with urinary incontinence. It is no longer available for new patients and is maintained only for servicing and repair of existing implants, serving healthcare providers with patients already implanted.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-12-24
Description

Collaboration with MintNeuro (Imperial College London spinout) to develop next-generation version of the Picostim device using specialized semiconductor chips that could make devices up to 1,000 times smaller than current technologies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-05
Description

Amber Therapeutics acquired Bioinduction Limited and its Picostim DyNeuMo neuromodulation platform in September 2023. The acquisition consolidated Amber as an integrated manufacturer and developer of neuromodulation devices and supports the advancement of its Amber-UI therapy through clinical trials and commercialisation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-29
Description

Academic collaboration led by University of Oxford for the Picostim DyNeuMo research platform. Amber supplies devices for multiple first-in-human trials sponsored by academic collaborators. Co-founders Tim Denison (joint appointment in Engineering Science and Clinical Neurosciences) and company origins tie to Oxford.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Axonics
TypeDirect peer
Description

Axonics is a direct competitor with an FDA-approved rechargeable sacral neuromodulation system (r-SNM) for urge incontinence and overactive bladder. Most directly comparable commercial neuromodulation peer targeting the same urology call point and patient population.

TypeBroad incumbent
Description

Medtronic's InterStim sacral neuromodulation system is the established market leader in implantable neuromodulation for urinary incontinence. Co-founder Tim Denison's prior technical leadership at Medtronic makes it a closely watched incumbent competitor and benchmark.

TypeDirect peer
Description

BlueWind Medical develops the Revi miniature tibial neuromodulation system for urge incontinence — a direct emerging competitor pursuing a different implant site (tibial vs. pudendal) but addressing the same unmet need Amber targets.

TypeDirect peer
Description

Valencia Technologies developed the eCoin leadless, nickel-sized, battery-free tibial nerve stimulator for urge urinary incontinence — a minimally invasive direct competitor in the incontinence neuromodulation space.

TypeDirect peer
Description

Laborie acquired Pelvalon (Eclipse vaginal insert for fecal incontinence) and Cogentix (Urgent PC percutaneous tibial neuromodulation) — directly competing in the pelvic floor and incontinence neuromodulation/treatment space.

TypeEmerging player
Description

Saluda Medical commercializes the Evoke closed-loop spinal cord stimulation system, making it the closest technological analogue to Amber's closed-loop DyNeuMo platform — relevant for IP/competitive positioning and exit comparables.

TypeEmerging player
Description

Nalu Medical developed a miniaturized, battery-free peripheral nerve stimulation system — a relevant emerging peer in the miniaturized implantable neuromodulation category Amber is targeting via MintNeuro.

TypeBroad incumbent
Description

Boston Scientific operates a broad neuromodulation portfolio (Vercise DBS, Spectra WaveWriter SCS, Vertiflex) and is a potential strategic acquirer or competitor as Amber expands beyond UI into adjacent indications.

TypeBroad incumbent
Description

Abbott's neuromodulation franchise (Proclaim DRG, Infinity DBS, Eterna SCS) makes it a relevant broad incumbent and potential strategic acquirer as Amber commercializes its closed-loop platform.

TypeEmerging player
Description

Elidah/Nuroflux develops wearable neuromodulation devices for stress urinary incontinence in women — an adjacent emerging peer pursuing a non-invasive alternative in the same MUI/UI market segment Amber addresses.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amber Therapeutics

Implantable Neuromodulation Medical Devicesamber-tx.com

Amber Therapeutics is a UK medical device company developing Amber-UI, a fully implantable, closed-loop neuromodulation therapy that targets the pudendal nerve to treat women with mixed urinary incontinence, with a US registration trial planned for 2026.

What Amber Therapeutics does

Amber Therapeutics is a UK-based, venture-backed medical device company founded in 2021 by Aidan Crawley, Tim Denison, Stefan De Wachter, and Charles Knowles to develop adaptive neuromodulation therapies for areas of unmet clinical need. The company's lead program, Amber-UI, is a fully implantable neurostimulation therapy that targets the pudendal nerve to treat women with mixed urinary incontinence (MUI) — a population of roughly 40 million symptomatic women in the US of whom only 16 million receive any therapy. Amber's core technology is the Picostim System running the DyNeuMo firmware platform, which combines integrated sensing with adaptive closed-loop stimulation in a single implantable pulse generator, originally developed for deep brain stimulation and acquired via the September 2023 Bioinduction transaction.

The Picostim DyNeuMo platform is positioned as the first singular therapy capable of addressing both urge and stress components of MUI in a single device, validated in the AURA-2 first-in-human study (13 women at University Hospital Antwerp) which met primary safety/feasibility endpoints and showed pilot efficacy and quality-of-life improvements. A US registration trial is planned for 2026 to support FDA approval, and Amber has extended its pipeline through ongoing studies (SPARKS, CADET, MINDS, EPIONE) and a December 2025 collaboration with MintNeuro on next-generation miniaturized semiconductor chips.

Amber is pre-revenue and pre-commercial; its go-to-market is built around clinical trials with academic medical centers and a planned enterprise field sales motion to urology/pelvic-health specialists and hospital systems once regulatory approval is obtained. Revenue mechanics, once commercial, will be hardware sales of the implantable Picostim device plus procedure-driven service revenue, with pricing not publicly disclosed and distribution expected through direct engagement with hospital procurement. The company has raised $100 million in Series A financing (June 2024, led by NEA) and is backed by F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises, and 8VC.

Amber Therapeutics firmographics

Firmographics
Name
Amber Therapeutics
Legal name
Amber Therapeutics Ltd.
Website
https://amber-tx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Amber Therapeutics is a UK medical device company developing Amber-UI, a fully implantable, closed-loop neuromodulation therapy that targets the pudendal nerve to treat women with mixed urinary incontinence, with a US registration trial planned for 2026.
Ownership category
akta.pro rank

Amber Therapeutics industry classification

Industry
Product category
Implantable Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Implantable neuromodulation devices
  • Bioelectronic medical devices
  • Urinary incontinence therapy
  • Adaptive neurostimulation
  • Pelvic floor neuromodulation

Where Amber Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Amber Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Implantable Neuromodulation Devices: Amber Therapeutics generates revenue through the sale of its Picostim System and Amber-UI therapy devices - fully implantable neurostimulation devices for treating mixed urinary incontinence. The company also acquired Bioinduction Limited, consolidating itself as an integrated manufacturer and developer of neuromodulation devices.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Amber Therapeutics product offering

Product offering

Core offering

Amber Therapeutics develops and manufactures fully implantable neuromodulation devices, primarily the Picostim System powered by its DyNeuMo firmware, to deliver adaptive pudendal nerve stimulation. Its lead therapy, Amber-UI, is the first single therapy designed to treat mixed urinary incontinence (both urge and stress incontinence) in women. The company is advancing the therapy through clinical trials (AURA-2) toward FDA approval, and serves as an integrated developer and manufacturer following its 2023 acquisition of Bioinduction Limited.

Product overview

Amber Therapeutics develops a unified product ecosystem centered on its Picostim System with DyNeuMo firmware platform, which serves as the foundation for its Amber-UI therapy. The Picostim is a fully implantable device that combines stimulation and sensing capabilities to deliver adaptive closed-loop neuromodulation for mixed urinary incontinence. The company also maintains the legacy Finetech-Brindley SARS System (no longer for new patients). The portfolio architecture consists of the Picostim hardware platform with integrated sensors, the DyNeuMo adaptive firmware enabling real-time therapy adjustment, and the Amber-UI therapy which represents the configured treatment for urinary incontinence.

Differentiator

Problem solved

Functional benefit

Brands

  • Amber-UI: Adaptive neuromodulation therapy for treating women suffering with mixed urinary incontinence (both urge and stress incontinence), targeting the pudendal nerve with a fully implantable device.
  • Picostim DyNeuMo
  • AURA-2

Products and services

  • Amber-UI Amber-UI is an adaptive neuromodulation therapy for treating women with mixed urinary incontinence (both urge and stress incontinence). It uses a fully implantable Picostim System that targets the pudendal nerve, combining stimulation and sensing of physiological responses through adaptive algorithms configurable to individual patient needs. It is intended for healthcare providers and urology/pelvic health specialists treating refractory patients.
  • Picostim System Picostim is a fully implantable neurostimulation device with integrated sensors capable of both stimulating and sensing physiological responses. It is configured to deliver adaptive closed-loop neuromodulation targeting the pudendal nerve for the Amber-UI therapy and is sold to clinical and hospital customers.
  • Finetech-Brindley SARS System The Finetech-Brindley SARS System is a legacy implantable bladder control system for patients with urinary incontinence. It is no longer available for new patients and is maintained only for servicing and repair of existing implants, serving healthcare providers with patients already implanted.

Quantifiable outcome

  • Primary aim of demonstrating safety and feasibility of surgical procedure fulfilled in AURA-2 study
  • +3 more outcomes

Companies that use Amber Therapeutics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Amber Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Amber Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • MintNeuromajorTechnology or Integration · 24 December 2025Collaboration with MintNeuro (Imperial College London spinout) to develop next-generation version of the Picostim device using specialized semiconductor chips that could make devices up to 1,000 times smaller than current technologies.
  • Bioinduction LimitedcoreStrategic or Co-development Partner · 5 September 2023Amber Therapeutics acquired Bioinduction Limited and its Picostim DyNeuMo neuromodulation platform in September 2023. The acquisition consolidated Amber as an integrated manufacturer and developer of neuromodulation devices and supports the advancement of its Amber-UI therapy through clinical trials and commercialisation.
  • University of OxfordcoreStrategic or Co-development Partner · 29 November 2022Academic collaboration led by University of Oxford for the Picostim DyNeuMo research platform. Amber supplies devices for multiple first-in-human trials sponsored by academic collaborators. Co-founders Tim Denison (joint appointment in Engineering Science and Clinical Neurosciences) and company origins tie to Oxford.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Amber Therapeutics competitors and assessment

Company assessment

Direct peers

  • Axonics: Axonics is a direct competitor with an FDA-approved rechargeable sacral neuromodulation system (r-SNM) for urge incontinence and overactive bladder. Most directly comparable commercial neuromodulation peer targeting the same urology call point and patient population.
  • BlueWind Medical: BlueWind Medical develops the Revi miniature tibial neuromodulation system for urge incontinence — a direct emerging competitor pursuing a different implant site (tibial vs. pudendal) but addressing the same unmet need Amber targets.
  • Valencia Technologies: Valencia Technologies developed the eCoin leadless, nickel-sized, battery-free tibial nerve stimulator for urge urinary incontinence — a minimally invasive direct competitor in the incontinence neuromodulation space.
  • Laborie (Pelvalon / Cogentix): Laborie acquired Pelvalon (Eclipse vaginal insert for fecal incontinence) and Cogentix (Urgent PC percutaneous tibial neuromodulation) — directly competing in the pelvic floor and incontinence neuromodulation/treatment space.

Broad incumbents

  • Medtronic: Medtronic's InterStim sacral neuromodulation system is the established market leader in implantable neuromodulation for urinary incontinence. Co-founder Tim Denison's prior technical leadership at Medtronic makes it a closely watched incumbent competitor and benchmark.
  • Boston Scientific: Boston Scientific operates a broad neuromodulation portfolio (Vercise DBS, Spectra WaveWriter SCS, Vertiflex) and is a potential strategic acquirer or competitor as Amber expands beyond UI into adjacent indications.
  • Abbott: Abbott's neuromodulation franchise (Proclaim DRG, Infinity DBS, Eterna SCS) makes it a relevant broad incumbent and potential strategic acquirer as Amber commercializes its closed-loop platform.

Emerging players

  • Saluda Medical: Saluda Medical commercializes the Evoke closed-loop spinal cord stimulation system, making it the closest technological analogue to Amber's closed-loop DyNeuMo platform — relevant for IP/competitive positioning and exit comparables.
  • Nalu Medical: Nalu Medical developed a miniaturized, battery-free peripheral nerve stimulation system — a relevant emerging peer in the miniaturized implantable neuromodulation category Amber is targeting via MintNeuro.
  • Nuroflux (formerly Elidah): Elidah/Nuroflux develops wearable neuromodulation devices for stress urinary incontinence in women — an adjacent emerging peer pursuing a non-invasive alternative in the same MUI/UI market segment Amber addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Amber Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amber Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Amber Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Amber Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amber Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amber Therapeutics

What does Amber Therapeutics do?

Amber Therapeutics develops and manufactures fully implantable neuromodulation devices, primarily the Picostim System powered by its DyNeuMo firmware, to deliver adaptive pudendal nerve stimulation. Its lead therapy, Amber-UI, is the first single therapy designed to treat mixed urinary incontinence (both urge and stress incontinence) in women. The company is advancing the therapy through clinical trials (AURA-2) toward FDA approval, and serves as an integrated developer and manufacturer following its 2023 acquisition of Bioinduction Limited.

Is Amber Therapeutics a public or private company?

Amber Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Amber Therapeutics founded?

Amber Therapeutics was founded in 2021. It employs 51 to 100 people.

Where is Amber Therapeutics based?

Amber Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does Amber Therapeutics make money?

One revenue line is on record: implantable Neuromodulation Devices.

Who are Amber Therapeutics's main competitors?

Direct peers on record are Axonics, BlueWind Medical, Valencia Technologies and Laborie (Pelvalon / Cogentix). Broad incumbents are Medtronic, Boston Scientific and Abbott. Emerging players are Saluda Medical, Nalu Medical and Nuroflux (formerly Elidah).

Does Amber Therapeutics have an API?

No public API is recorded for Amber Therapeutics.

What industry is Amber Therapeutics in?

Amber Therapeutics's product category is Implantable Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerBrain pacemaker market to hit USD 3.4BThe brain pacemaker market is projected to reach $3.4 billion by 2030, growing at a compound annual growth rate of 13.2%, driven by rising demand for dual-channel programmable pacemakers, broader clinical adoption, and technological advancements in neuromodulation devices. In September 2023, UK-based Amber Therapeutics acquired Bioinduction Limited along with its Picostim DyNeuMo neuromodulation therapy platform, positioning Amber as an integrated developer and manufacturer of intelligent closed-loop neuromodulation treatments. Medtronic introduced the Percept RC deep brain stimulation system in January 2024, featuring BrainSense technology that enables continuous brain signal monitoring for personalized patient therapy.openPR.comKey Factors and Emerging Trends Shaping the Implantable Neurostimulators Market LandscapeThe implantable neurostimulators market is projected to grow from $5.34 billion in 2021 to $11.44 billion by 2030, representing a compound annual growth rate of 11.0%, driven by technological advancements, an aging population, and expanded clinical evidence supporting neuromodulation therapies. In September 2023, UK-based med-tech company Amber Therapeutics Ltd. acquired Bioinduction Ltd. to strengthen its capabilities in developing neuromodulation therapies for mixed urinary incontinence. In December 2024, Medtronic launched its FDA-approved Percept RC neurostimulator in India, targeting neurological conditions such as Parkinson's disease, essential tremor, dystonia, and epilepsy.openPR.comAn Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Electrical Stimulation Devices MarketThe electrical stimulation devices market is projected to reach $13.22 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.3%, driven by personalized neuromodulation therapies, smart implantable devices, and remote monitoring technologies. A notable acquisition occurred in September 2023 when UK-based Amber Therapeutics Ltd. acquired Bioinduction Limited, securing full control over Picostim-based hardware development and accelerating its Amber-UI neuromodulation therapy. In May 2024, US-based Soterix Medical Inc. introduced the MxN-GO EEG system, an integrated wireless platform combining high-definition transcranial electrical stimulation with EEG monitoring.openPR.comTop Players and Market Competition in the Brain Pacemaker IndustryThe global brain pacemaker market is projected to reach $3.4 billion by 2030, growing at a compound annual growth rate of 13.2%, driven by technological advances, rising demand for dual-channel programmable pacemakers, and expanded clinical applications for conditions such as Parkinson's disease and obsessive-compulsive disorder. In September 2023, UK-based Amber Therapeutics acquired Bioinduction Limited along with its Picostim DyNeuMo neuromodulation therapy platform, transforming Amber Therapeutics into a fully integrated developer and manufacturer of intelligent closed-loop neuromodulation therapies. In January 2024, Medtronic launched the Percept RC deep brain stimulation system, currently the smallest and thinnest dual-channel neurostimulator available, incorporating the company's BrainSense technology for continuous brain signal monitoring.GlobeNewswireAmber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in theAmber Therapeutics announced new board and leadership appointments, opened its UK headquarters at Harwell, and expanded its AURA-4X study for mixed urinary incontinence to multiple European sites. The company aims to advance toward a US pivotal trial following its $100 million Series A financing.BebeezFrom labs to market: 10 promising biotech startups based in the UK – BeBeez InternationalTen UK biotech startups are profiled, including Amber Therapeutics, Ascend Gene & Cell Therapies, and Tenpoint Therapeutics. The UK biotech sector raised £1.8 billion in 2023, leading Europe in cell and gene therapy investments. The startups span neuromodulation, sustainable packaging, and regenerative therapies.University of OxfordTech transfer partnership between universities creates company to transform care for millions of womenAmber Therapeutics, a university-backed startup, raised $100 million in a Series A round led by New Enterprise Associates. The funding will support development of Amber-UI, an implantable therapy for mixed urinary incontinence, with clinical trials and US approval sought.BusinessCloudMedTech’s £80m raise could treat millions of womenAmber Therapeutics raised nearly £80 million in a Series A round led by NEA to develop Amber-UI, an adaptive neuromodulation therapy for mixed urinary incontinence. The funds will support pilot and pivotal studies toward US regulatory approval, with results expected in the second half of 2024.GlobeNewswireAmber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA ApprovalAmber Therapeutics closed a $100 million Series A financing led by New Enterprise Associates to advance its Amber-UI neuromodulation therapy for mixed urinary incontinence. The funds will support pilot and pivotal studies toward US FDA approval, with results expected in the second half of 2024.MassDeviceAmber Therapeutics raises $100M Series A to support neuromod techAmber Therapeutics closed a $100 million Series A financing round led by New Enterprise Associates to fund the development of its adaptive neuromodulation therapy for mixed urinary incontinence. The company plans to utilize these funds to advance its Amber-UI system through pilot studies in Europe and a pivotal trial in the U.S., aiming for regulatory approval. Early results have shown promising safety, feasibility, and efficacy signals, with full study results expected in the second half of 2024.